Long-term follow-up results of the ZUMA-1 trial of anti-CD19 CAR T-cells for non-Hodgkin lymphoma
Prophylactic treatment for CAR T-cell toxicity shows promising results
Multiple myeloma: genomic evolution
Jonathan Keats et al.
The use of CAR T-cells in multiple myeloma
Adam Cohen et al.
ZUMA-1 trial: FDA approval and follow-up of CAR T-cell product axicabtagene ciloleucel